DMII 10-K & 10-Q changes, risk factors and insider trading
Drugs Made In America Acquisition II Corp. (also DMIIR, DMIIU) · Nasdaq · Blank Checks · CIK 2040475 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Comparison not available: Not available: fewer than two 10-K filings on EDGAR to compare (only one so far)..
What changed in the latest 10-Q
Risk Factors
No wording changes found in this section.
Full comparison: every changed paragraph (0)
Management's Discussion & Analysis (MD&A)
Largest changes
For thesee in full comparisonthreesix months endedMarch,June3130,2025,2026, we hadanetlossincome of$59,327,$8,734,276, which consistsentirelyof general and administrativecosts.costs of $244,257, offset by interest earned on cash and investments held in the trust account of $8,948,533 and a $30,000 gain from the recovery of credit losses.
For the three months endedsee in full comparisonMarchJune31,30, 2026, we had net income of$4,337,820,$4,396,456, which consists of general and administrative costs of$132,030,$112,227, offset by interest earned on cash and investments held in the trust account of$4,439,850 and a $30,000 gain from the recovery of credit losses.$4,508,683.
“For the three months ended June, 30 2025, we had a net loss of $38,073, which consists entirely of general and administrative costs.”see in full comparison
“For the six months ended June, 30 2025, we had a net loss of $97,400, which consists entirely of general and administrative costs.”see in full comparison
Full comparison: every changed paragraph (7)
We have neither engaged in any operations nor
generated any revenues to date. Our only activities from August 23, 2024 (inception) through MarchJune 31,30, 2026 were organizational activities,
those necessary to prepare for the Initial Public Offering, described below, and subsequent to the Initial Public Offering, identifying
a target company for an initial business combination. We do not expect to generate any operating revenues until after the completion
of our initial business combination. We generate non-operating income in the form of interest earned on cash and investments held in
the trust account. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance),
as well as for due diligence expenses.
For the three months ended MarchJune 31,30, 2026, we
had net income of $4,337,820,$4,396,456, which consists of general and administrative costs of $132,030,$112,227, offset by interest earned on cash and investments
held in the trust account of $4,439,850 and a $30,000 gain from the recovery of credit losses.$4,508,683.
For the threesix months ended March,June 3130, 2025,2026, we
had a net lossincome of $59,327,$8,734,276, which consists entirely of general and administrative costs.costs of $244,257, offset by interest earned on cash and investments held in the trust account of $8,948,533 and a $30,000 gain from the recovery of credit losses.
For the three months ended June, 30 2025, we had a net loss of $38,073, which consists entirely of general and administrative costs.
For the six months ended June, 30 2025, we had a net loss of $97,400, which consists entirely of general and administrative costs.
As of MarchJune 31,30, 2026 and December 31, 2025 we
had cash of $347,720$174,974 and $223, respectively. Until the consummation of the Initial Public Offering, our only source of liquidity was an
initial purchase of ordinary shares by the sponsor and loans from our sponsor.
We have no obligations, assets or liabilities,
which would be considered off-balance sheet arrangements as of MarchJune 31,30, 2026. We do not participate in transactions that create relationships
with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established
for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements,
established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.
DMII insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
No Form 4 stock transactions in this period.
Well-known investors holding DMII (13F)
| Investor | Quarter | Shares | Reported value | % of their 13F | Change vs prior quarter |
|---|---|---|---|---|---|
| Millennium Management (Israel Englander) | 2026-06-30 | 1,993,558 | $20.1M | 0.01% | Added 1% |
| D. E. Shaw & Co. | 2026-06-30 | 1,475,000 | $14.8M | 0.01% | Added 6% |
| Two Sigma Investments | 2026-06-30 | 886,544 | $8.9M | 0.01% | No change |
| Millennium Management (Israel Englander) | 2026-06-30 | 2,000,000 | $160.0K | 0.0% | No change |
| D. E. Shaw & Co. | 2026-06-30 | 1,000,000 | $72.7K | 0.0% | No change |